Phenotype
|
Fish
|
Conditions
|
Figures
|
skeletal muscle neuromuscular junction morphology, abnormal
|
AB + MO1-dag1 + MO2-dag1
|
standard conditions
|
Fig. 6
from Bailey et al., 2019
|
skeletal muscle neuromuscular junction morphology, abnormal
|
AB + MO1-dag1 + MO2-dag1
|
chemical treatment by environment: NAD
|
Fig. 6
from Bailey et al., 2019
|
embryo development delayed, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2
from Parsons et al., 2002
|
caudal fin kinked, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 5
from Moore et al., 2008
|
myotome muscle tendon junction malformed, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 1
from Goody et al., 2012
|
vertical myoseptum malformed, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 1
from Goody et al., 2012
|
vertical myoseptum basement membrane irregular spatial pattern, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 6
from Goody et al., 2012
|
musculoskeletal movement disrupted, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2
from Parsons et al., 2002
|
post-vent region muscle cell morphology, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 5
from Lefebvre et al., 2007
|
muscle disorganized, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 4
from Parsons et al., 2002
|
muscle necrotic, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 4
from Parsons et al., 2002
|
post-vent region increased curvature, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2
from Parsons et al., 2002
|
muscle sarcomere morphology, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 4
from Parsons et al., 2002
|
myotome basement membrane morphology, ameliorated
|
WT + MO1-dag1
|
chemical treatment: NAD(+)
|
Fig. 2
from Goody et al., 2012
|
locomotion involved in locomotory behavior decreased rate, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 8
from Goody et al., 2012
|
muscle sarcomere decreased amount, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 4
from Parsons et al., 2002
|
myoseptum broken, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 4
from Goody et al., 2010
|
myotome muscle tendon junction disorganized, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 1
from Goody et al., 2012
|
muscle sarcoplasmic reticulum unstructured, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 4
from Parsons et al., 2002
|
myotome muscle cell detached from myotome muscle tendon junction, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2 ,
Fig. 6
from Goody et al., 2012
|
whole organism dystrophic, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2
from Parsons et al., 2002
|
ventral fin fold decreased size, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2
from Parsons et al., 2002
|
muscle attachment disrupted, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. S2
from Postel et al., 2008
|
locomotion involved in locomotory behavior decreased rate, abnormal
|
WT + MO1-dag1
|
chemical treatment: NAD(+)
|
Fig. 8
from Goody et al., 2012
|
trunk musculature skeletal muscle cell retracted, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. S2
from Postel et al., 2008
|
myotome muscle cell attached to myotome muscle tendon junction, ameliorated
|
WT + MO1-dag1
|
chemical treatment: NAD(+)
|
Fig. 2
from Goody et al., 2012
|
myotome basement membrane malformed, abnormal
|
WT + MO1-dag1
|
standard conditions
|
Fig. 2
from Goody et al., 2012
|
embryo development delayed, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 2
from Wood et al., 2011
|
somite intersegmental vessel absent, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 5
from Wood et al., 2011
|
larval locomotory behavior disrupted, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 2
from Wood et al., 2011
|
somite myoseptum deformed, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 4
from Wood et al., 2011
|
somite intersegmental vessel disorganized, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 5
from Wood et al., 2011
|
whole organism dead, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 2
from Wood et al., 2011
|
post-vent region decreased length, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 2
from Wood et al., 2011
|
dorsal aorta intersegmental vessel separated from dorsal longitudinal anastomotic vessel, abnormal
|
y1Tg + MO1-dag1
|
standard conditions
|
Fig. 5
from Wood et al., 2011
|
post-vent region skeletal muscle cell retracted, abnormal
|
ilkhu801/hu801 + MO1-dag1
|
standard conditions
|
Fig. 1
from Postel et al., 2008
|
muscle attachment disrupted, abnormal
|
ilkhu801/hu801 + MO1-dag1
|
standard conditions
|
Fig. 1
from Postel et al., 2008
|
receptor clustering disrupted, abnormal
|
musktbr307/tbr307 + MO1-dag1
|
standard conditions
|
Fig. 3
from Lefebvre et al., 2007
|
skeletal muscle cell detached from vertical myoseptum, abnormal
|
AB/TU + MO1-dag1 + MO1-lama2
|
standard conditions
|
Fig. 6
from Charvet et al., 2013
|
muscle attachment decreased process quality, abnormal
|
AB/TU + MO1-dag1 + MO1-lama2
|
standard conditions
|
Fig. 6
from Charvet et al., 2013
|
myotome muscle cell degenerate, abnormal
|
WT + MO1-dag1 + MO1-itga6a + MO2-itga6a
|
standard conditions
|
Fig. 5
from Goody et al., 2012
|
vertical myoseptum U-shaped, abnormal
|
WT + MO1-dag1 + MO1-itga6a + MO2-itga6a
|
standard conditions
|
Fig. 5
from Goody et al., 2012
|
myotome muscle tendon junction U-shaped, abnormal
|
WT + MO1-dag1 + MO1-itga6a + MO2-itga6a
|
chemical treatment: NAD(+)
|
Fig. 5
from Goody et al., 2012
|
vertical myoseptum U-shaped, abnormal
|
WT + MO1-dag1 + MO1-itga6a + MO2-itga6a
|
chemical treatment: NAD(+)
|
Fig. 5
from Goody et al., 2012
|
myotome muscle tendon junction U-shaped, abnormal
|
WT + MO1-dag1 + MO1-itga6a + MO2-itga6a
|
standard conditions
|
Fig. 5
from Goody et al., 2012
|
myotome muscle cell degenerate, abnormal
|
WT + MO1-dag1 + MO1-itga6a + MO2-itga6a
|
chemical treatment: NAD(+)
|
Fig. 5
from Goody et al., 2012
|
myotome muscle cell degenerate, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
standard conditions
|
Fig. 3
from Goody et al., 2012
|
myotome muscle tendon junction malformed, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
chemical treatment: NAD(+)
|
Fig. 3
from Goody et al., 2012
|
myotome muscle cell detached from myotome muscle tendon junction, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
chemical treatment: NAD(+)
|
Fig. 3
from Goody et al., 2012
|
myotome muscle cell degenerate, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
chemical treatment: NAD(+)
|
Fig. 3
from Goody et al., 2012
|
vertical myoseptum malformed, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
standard conditions
|
Fig. 3
from Goody et al., 2012
|
myotome muscle cell detached from myotome muscle tendon junction, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
standard conditions
|
Fig. 3
from Goody et al., 2012
|
vertical myoseptum malformed, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
chemical treatment: NAD(+)
|
Fig. 3
from Goody et al., 2012
|
myotome muscle tendon junction malformed, abnormal
|
WT + MO1-dag1 + MO2-itga7
|
standard conditions
|
Fig. 3
from Goody et al., 2012
|
locomotion involved in locomotory behavior decreased rate, abnormal
|
mai1Tg + MO1-dag1
|
standard conditions
|
Fig. 8
from Goody et al., 2012
|
myotome muscle cell detached from myotome muscle tendon junction, abnormal
|
mai1Tg + MO1-dag1
|
standard conditions
|
Fig. 6
from Goody et al., 2012
|